CMS advises Aenova on merger with Haupt Pharma

Stuttgart – The Aenova Group signed an agreement with the owners of Haupt Pharma Group in mid-October to acquire a majority of the the group. Aenova is a significant player in the pharmaceutical and healthcare sector. Haupt Pharma AG specialises in development and con-tract manufacturing for the pharmaceutical industry. By acquiring Haupt Pharma, the Aenova Group has gained a partner with which it can expand its portfolio strategically. The transaction is currently awaiting approval from the competition authorities.

An international team led by Hamburg-based M&A partner Dr Jacob Siebert advised Aenova and majority shareholder BC Partners on all aspects of the due diligence and contract negotia-tions. CMS Hasche Sigle was supported by CMS law firms in Italy, France, Switzerland, Aus-tria and Luxembourg and by World Law Group partner firm City-Yuwa Partners.

BC Partners acquired the Aenova Group in September 2012 from the previous owners, Bridgepoint, adding the Temmler Group shortly afterwards. Almost a year after its successful acquisition of the Temmler Group, annual sales of the Aenova Group rose on completion by around 60% to more than EUR 750 million. A team including Dr Udo Simmat, Dr Tobias Schneider and Dr Jacob Siebert also advised on all aspects of these previous transactions

• CMS Hasche Sigle
  Dr Udo Simmat, M&A/Private Equity
  Dr Jacob Siebert, Lead Partner, M&A/Private Equity
  Johannes Braun, M&A/Due Diligence
  Dr Nils Maack, M&A
  Stefan Lüft, Pharma
  Dr Jakob Steiff, Regulatory
  Dr Eva-Maria Burkard, Regulatory
  Beate Engin, Regulatory
  Dr Antje-Kathrin Uhl, Employment
  Dr Tobias Polloczek, Employment/Pensions
  Dr Jan Dombrowski, IP
  Bernhard Freund, IT
  Dr Marc Seibold, Finance
  Dr Andreas Grunert, Finance
  Dr Andreas Heim, Commercial
  Dr Stefan Voss, Real Estate
  Dr Harald Kahlenberg, Competition
  Dr Hannes Schwinn, Competition
  Dr Olaf Thießen, M&A/Tax
• CMS Adonnino Ascoli & Cavasola Scamoni (Milan/Rome)
  Pietro Cavasola, M&A, Corporate
  Serena Carroli, Due Diligence
• CMS Bureau Francis Lefebvre (Paris)
  Anne-Laure Villedieu, Regulatory/Pharma
  Jacques Isnard, Corporate/M&A
  Maité Ollivier, Employment
• CMS von Erlach Henrici (Zurich)
  Dr Kaspar Landolt, Finance
• CMS DeBacker Luxembourg
  Vivian Walry, Finance
• CMS Reich-Rohrwig Hainz (Vienna)
  Bernt Elsner, Competition
• City-Yuwa Partners (Tokyo)
  Mikio Tanaka, Corporate/Due Diligence
  Akira Nagasaki, Corporate/Due Diligence
  
  

For further information, please contact:

Nicolas Merigeau, NewCap
nmerigeau@newcap.fr
+33 1 44 71 94 98

CMS Bureau Francis Lefebvre
Florence Jouffroy, Directeur du Marketing et de la Communication
Laetitia Mostowski, Responsable Communication externe
florence.jouffroy@cms-bfl.com
laetitia.mostowski@cms-bfl.com
+33 1 47 38 40 32 / 40 74